BOSTON SCIENTIFIC CORP (BSX) Stock Fundamental Analysis
NYSE:BSX • US1011371077
76.85 USD
+1.1 (+1.45%)
At close: Feb 27, 2026
76.85 USD
0 (0%)
After Hours: 2/27/2026, 8:04:00 PM
BSX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. While BSX has a great profitability rating, there are some minor concerns on its financial health. BSX is growing strongly while it is still valued neutral. This is a good combination! These ratings could make BSX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
- In the past year BSX was profitable.
- In the past year BSX had a positive cash flow from operations.
- BSX had positive earnings in each of the past 5 years.
- BSX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 6.54%, BSX belongs to the best of the industry, outperforming 86.49% of the companies in the same industry.
- With an excellent Return On Equity value of 11.93%, BSX belongs to the best of the industry, outperforming 88.65% of the companies in the same industry.
- The Return On Invested Capital of BSX (8.35%) is better than 84.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.35% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of BSX (14.42%) is better than 91.35% of its industry peers.
- In the last couple of years the Profit Margin of BSX has grown nicely.
- Looking at the Operating Margin, with a value of 19.40%, BSX belongs to the top of the industry, outperforming 91.89% of the companies in the same industry.
- BSX's Operating Margin has improved in the last couple of years.
- BSX has a better Gross Margin (68.57%) than 75.68% of its industry peers.
- In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
- BSX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.52 indicates that BSX is not in any danger for bankruptcy at the moment.
- BSX's Altman-Z score of 4.52 is fine compared to the rest of the industry. BSX outperforms 75.14% of its industry peers.
- BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
- BSX has a better Debt to FCF ratio (3.03) than 82.70% of its industry peers.
- A Debt/Equity ratio of 0.48 indicates that BSX is not too dependend on debt financing.
- BSX has a Debt to Equity ratio (0.48) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 4.52 |
ROIC/WACC0.86
WACC9.69%
2.3 Liquidity
- A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
- The Current ratio of BSX (1.51) is worse than 74.05% of its industry peers.
- BSX has a Quick Ratio of 1.51. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
- BSX's Quick ratio of 0.96 is on the low side compared to the rest of the industry. BSX is outperformed by 78.92% of its industry peers.
- The current and quick ratio evaluation for BSX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
- BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.51%, which is quite impressive.
- BSX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.01% yearly.
- Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.88% in the last year.
- Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 15.16% on average per year.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
3.2 Future
- BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.13% yearly.
- The Revenue is expected to grow by 10.46% on average over the next years. This is quite good.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue Next Year10.95%
Revenue Next 2Y10.73%
Revenue Next 3Y10.6%
Revenue Next 5Y10.46%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 25.20, which means the current valuation is very expensive for BSX.
- BSX's Price/Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 77.30% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BSX to the average of the S&P500 Index (27.07), we can say BSX is valued inline with the index average.
- Based on the Price/Forward Earnings ratio of 21.94, the valuation of BSX can be described as rather expensive.
- BSX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 78.92% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BSX to the average of the S&P500 Index (28.05), we can say BSX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.2 | ||
| Fwd PE | 21.94 |
4.2 Price Multiples
- BSX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BSX is cheaper than 72.97% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BSX is valued a bit cheaper than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.81 | ||
| EV/EBITDA | 24.35 |
4.3 Compensation for Growth
- BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of BSX may justify a higher PE ratio.
- BSX's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)0.97
EPS Next 2Y14.13%
EPS Next 3Y13.68%
5. Dividend
5.1 Amount
- No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
76.85
+1.1 (+1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)04-21 2026-04-21/bmo
Inst Owners94.07%
Inst Owner Change2.68%
Ins Owners0.15%
Ins Owner Change2.4%
Market Cap113.97B
Revenue(TTM)20.07B
Net Income(TTM)2.79B
Analysts86
Price Target107.14 (39.41%)
Short Float %1.91%
Short Ratio1.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-15.34%
PT rev (3m)-16.46%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)-0.44%
Revenue NY rev (3m)-0.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.2 | ||
| Fwd PE | 21.94 | ||
| P/S | 5.89 | ||
| P/FCF | 29.81 | ||
| P/OCF | 24.64 | ||
| P/B | 4.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.35 |
EPS(TTM)3.05
EY3.97%
EPS(NY)3.5
Fwd EY4.56%
FCF(TTM)2.58
FCFY3.35%
OCF(TTM)3.12
OCFY4.06%
SpS13.05
BVpS15.77
TBVpS-1.34
PEG (NY)1.7
PEG (5Y)0.97
Graham Number32.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.35% | ||
| ROICexc | 8.65% | ||
| ROICexgc | 29.1% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 4.52 |
F-Score6
WACC9.69%
ROIC/WACC0.86
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.95%
Revenue Next 2Y10.73%
Revenue Next 3Y10.6%
Revenue Next 5Y10.46%
EBIT growth 1Y30.66%
EBIT growth 3Y24.06%
EBIT growth 5Y34.39%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y77.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.53%
OCF growth 3YN/A
OCF growth 5YN/A
BOSTON SCIENTIFIC CORP / BSX FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BSX.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 5 / 10 to BOSTON SCIENTIFIC CORP (BSX). This can be considered as Fairly Valued.
How profitable is BOSTON SCIENTIFIC CORP (BSX) stock?
BOSTON SCIENTIFIC CORP (BSX) has a profitability rating of 8 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX) is 25.2 and the Price/Book (PB) ratio is 4.87.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 14.83% in the next year.